SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443) (RKDA) — May 24, 2018

Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443)
Date: May 24, 2018 · CIK: 0001469443 · Accession: 0000000000-18-016126

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-224893

Date
May 24, 2018
Author
Sonia Bednarowski
Form
UPLOAD
Company
Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443)

Letter

May 24, 2018 Matthew Plavan Chief Financial Officer Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 105 Davis, CA 95618 Re:Arcadia Biosciences, Inc. Registration Statement on Form S-3 Filed May 11, 2018 File No. 333-224893 Dear Mr. Plavan: We have limited our review of your registration statement to those issues we have addressed in our comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Registration Statement on Form S-3 General 1.Please provide the basis for your conclusion that you are eligible to conduct a primary offering under General Instruction I.B.1 of Form S-3. Alternatively, to the extent you intend to rely on General Instruction I.B.6 of Form S-3, please include the information required by Instruction 7 on the prospectus cover page. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

FirstName LastNameMatthew Plavan Comapany NameArcadia Biosciences, Inc. May 24, 2018 Page 2 FirstName LastName Matthew Plavan Arcadia Biosciences, Inc. May 24, 2018 Page 2 Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Sonia Bednarowski at 202-551-3666 or Nolan McWilliams at 202-551- 3217 with any questions. Division of Corporation Finance Office of Transportation and Leisure

Show Raw Text
May 24, 2018
Matthew Plavan
Chief Financial Officer
Arcadia Biosciences, Inc.
202 Cousteau Place, Suite 105
Davis, CA 95618
Re:Arcadia Biosciences, Inc.
Registration Statement on Form S-3
Filed May 11, 2018
File No. 333-224893
Dear Mr. Plavan:
            We have limited our review of your registration statement to those issues we have
addressed in our comments.  In some of our comments, we may ask you to provide us with
information so we may better understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-3
General
1.Please provide the basis for your conclusion that you are eligible to conduct a primary
offering under General Instruction I.B.1 of Form S-3.  Alternatively, to the extent you
intend to rely on General Instruction I.B.6 of Form S-3, please include the information
required by Instruction 7 on the prospectus cover page.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

 FirstName LastNameMatthew  Plavan
 Comapany NameArcadia Biosciences, Inc.
 May 24, 2018 Page 2
 FirstName LastName
Matthew  Plavan
Arcadia Biosciences, Inc.
May 24, 2018
Page 2
            Refer to Rules 460 and 461 regarding requests for acceleration.  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
            Please contact Sonia Bednarowski at 202-551-3666 or Nolan McWilliams at 202-551-
3217 with any questions.
Division of Corporation Finance
Office of Transportation and Leisure